| scholarly article | Q13442814 |
| P50 | author | Colin Dunstan | Q43109492 |
| Thierry Facon | Q85789960 | ||
| Xavier Mariette | Q93104907 | ||
| P2093 | author name string | Allan Lipton | |
| Jean-Luc Harousseau | |||
| Jean-Jacques Body | |||
| Jean-Paul Fermand | |||
| Philip Greipp | |||
| Robert E Coleman | |||
| Catherine D Williams | |||
| Pirow J Bekker | |||
| Steven W Martin | |||
| Arline Nakanishi | |||
| Donna Holloway | |||
| Filip Geurs | |||
| P2860 | cites work | Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 |
| Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 | ||
| Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis | Q24324701 | ||
| Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL | Q24682139 | ||
| Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group | Q34747852 | ||
| A dose-finding study of zoledronate in hypercalcemic cancer patients | Q40799250 | ||
| A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3. | Q41687961 | ||
| The effect of a single dose of osteoprotegerin in postmenopausal women | Q43520860 | ||
| Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases | Q43563141 | ||
| Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group | Q46251476 | ||
| Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma | Q57905146 | ||
| Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group | Q71890854 | ||
| Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord | Q73766127 | ||
| Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group | Q74593419 | ||
| Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma | Q77337118 | ||
| P433 | issue | 3 Suppl | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| multiple myeloma | Q467635 | ||
| breast carcinoma | Q18555947 | ||
| P304 | page(s) | 887-892 | |
| P577 | publication date | 2003-02-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases | |
| P478 | volume | 97 |
| Q57184035 | A RANKL G278R mutation causing osteopetrosis identifies a functional amino acid essential for trimer assembly in RANKL and TNF |
| Q84656654 | A new role for OPG: Putting RANKL in its place |
| Q40101765 | A new xenograft model of myeloma bone disease demonstrating the efficacy of human mesenchymal stem cells expressing osteoprotegerin by lentiviral gene transfer |
| Q57904787 | Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor–κB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton |
| Q37780489 | An antibody against RANKL for the treatment of osteoporosis, inflammatory and malignant bone diseases |
| Q26863493 | Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences |
| Q37346958 | Arming a replicating adenovirus with osteoprotegerin reduces the tumor burden in a murine model of osteolytic bone metastases of breast cancer |
| Q35909592 | Assessment of therapeutic response in patients with metastatic bone disease |
| Q28265584 | Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab |
| Q36471234 | Biochemical markers of bone metabolism in multiple myeloma |
| Q36737426 | Bisphosphonate therapy for women with breast cancer and at high risk for osteoporosis. |
| Q50888455 | Bone Disease in Multiple Myeloma. |
| Q34001621 | Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention |
| Q36737006 | Bone disease in multiple myeloma |
| Q34045789 | Bone disease in multiple myeloma: pathophysiology and management. |
| Q36162703 | Bone marrow microenvironment and the identification of new targets for myeloma therapy |
| Q35095558 | Breast Cancer: Rank Ligand Inhibition. |
| Q30437441 | Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy |
| Q36925346 | Cellular mechanisms of multiple myeloma bone disease |
| Q37029680 | Cervical actinomycosis with spinal cord compression. Case report and literature review |
| Q35571242 | Classification of anticancer drugs—a new system based on therapeutic targets |
| Q37800534 | Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis |
| Q35901092 | Clinical development of anti-RANKL therapy |
| Q36762882 | Clinical targeting of the TNF and TNFR superfamilies |
| Q38026966 | Clinical usefulness of bone markers in prostate cancer with bone metastasis |
| Q91686329 | Combinatorial targeting of cancer bone metastasis using mRNA engineered stem cells |
| Q36158922 | Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets |
| Q34960778 | Contemporary therapeutic approaches targeting bone complications in prostate cancer |
| Q37248014 | Denosumab and giant cell tumour of bone-a review and future management considerations |
| Q37970800 | Denosumab for the management of bone disease in patients with solid tumors |
| Q35205280 | Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion |
| Q37974570 | Denosumab in patients with cancer-a surgical strike against the osteoclast |
| Q38010350 | Denosumab--a powerful RANKL inhibitor to stop lytic metastases and other bone loss actions by osteoclasts |
| Q43267044 | Denosumab: a promising drug for the prevention and treatment of osteoporosis |
| Q37307805 | Denosumab: an investigational drug for the management of postmenopausal osteoporosis |
| Q37594768 | Differential modulation of RANKL isoforms by human osteoarthritic subchondral bone osteoblasts: influence of osteotropic factors |
| Q28191731 | Disabling of receptor activator of nuclear factor-kappaB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo |
| Q37658767 | Emerging therapeutic targets in breast cancer bone metastasis |
| Q34182919 | Emerging therapies in metastatic bone pain |
| Q35588448 | Enhancement of periodontal tissue regeneration by transplantation of osteoprotegerin-engineered periodontal ligament stem cells |
| Q34099162 | Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club |
| Q28575953 | Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation |
| Q36644377 | Expression of osteoprotegerin from a replicating adenovirus inhibits the progression of prostate cancer bone metastases in a murine model |
| Q47322356 | Expression of receptor activator of NF-kappaB ligand (RANKL) mRNA in human multiple myeloma cells |
| Q51135670 | Formulation and in vitro and in vivo evaluation of a new osteoprotegerin-chitosan gel for bone tissue regeneration. |
| Q28076305 | From bones to blood pressure, developing novel biologic approaches targeting the osteoprotegein pathway for pulmonary vascular disease |
| Q36700779 | Functions of RANKL/RANK/OPG in bone modeling and remodeling |
| Q38090292 | Genes, molecules and patients--emerging topics to guide clinical pain research |
| Q55406267 | Genetic deletion of muscle RANK or selective inhibition of RANKL is not as effective as full-length OPG-fc in mitigating muscular dystrophy. |
| Q34674841 | Genetic factors influencing the risk of multiple myeloma bone disease |
| Q90442956 | Harnessing the versatile role of OPG in bone oncology: counterbalancing RANKL and TRAIL signaling and beyond |
| Q47141671 | Heterologous expression, purification and function of the extracellular domain of human RANK. |
| Q51119346 | Highlights from: The 39th Annual Meeting of the American Society of Clinical Oncology; Chicago, Illinois. |
| Q35115283 | Human mesenchymal stem cells as delivery of osteoprotegerin gene: homing and therapeutic effect for osteosarcoma |
| Q35549238 | Hypoxia, stem cells and bone tumor |
| Q36571484 | Importance of osteoprotegrin and receptor activator of nuclear factor κB in breast cancer response to hepatocyte growth factor and the bone microenvironment in vitro |
| Q36135381 | In vitro evaluation of osteoprotegerin in chitosan for potential bone defect applications |
| Q39109010 | Inhibition effect of enteropeptidase on RANKL-RANK signalling by cleavage of RANK. |
| Q36417317 | Inhibition of RANKL as a treatment for osteoporosis: preclinical and early clinical studies |
| Q54957173 | Invasion-Related Factors as Potential Diagnostic and Therapeutic Targets in Oral Squamous Cell Carcinoma-A Review. |
| Q28287394 | Key roles of the OPG-RANK-RANKL system in bone oncology |
| Q33862655 | Local application of osteoprotegerin-chitosan gel in critical-sized defects in a rabbit model |
| Q36968961 | Local delivery of osteoprotegerin inhibits mechanically mediated bone modeling in orthodontic tooth movement |
| Q38425187 | Local delivery of recombinant osteoprotegerin enhances postorthodontic tooth stability |
| Q28727655 | Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab |
| Q37106639 | Mechanisms modulating inflammatory osteolysis: a review with insights into therapeutic targets |
| Q36366450 | Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. |
| Q30439221 | Metastasis: a therapeutic target for cancer |
| Q36533587 | Metastatic bone cancer pain: etiology and treatment options |
| Q52613205 | Microsphere controlled drug delivery for local control of tooth movement. |
| Q38749233 | Molecular mechanisms, current management and next generation therapy in myeloma bone disease. |
| Q81318588 | Mouse models and the RANKL/OPG axis in myeloma bone disease |
| Q79798337 | Multiple myeloma |
| Q33953955 | Multiple myeloma and bone disease: pathogenesis and current therapeutic approaches. |
| Q38246241 | Myeloma bone disease: pathogenesis, current treatments and future targets |
| Q36146493 | Myeloma bone disease: pathophysiology and management. |
| Q37127171 | Neural progenitor cell-mediated delivery of osteoprotegerin limits disease progression in a preclinical model of neuroblastoma bone metastasis |
| Q35591086 | New insights into the pathophysiology and management of bone disease in multiple myeloma |
| Q51760981 | Novel RANK antagonists for the treatment of bone-resorptive disease: theoretical predictions and experimental validation. |
| Q47796713 | Novel RANKL DE-loop mutants antagonize RANK-mediated osteoclastogenesis |
| Q36703987 | Novel host response therapeutic approaches to treat periodontal diseases. |
| Q41135180 | OPG and PgR show similar cohort specific effects as prognostic factors in ER positive breast cancer |
| Q29547556 | Osteoclast differentiation and activation |
| Q36039925 | Osteolytic bone diseases: physiological analogues of bone resorption effectors as alternative therapeutic tools |
| Q38206487 | Osteoprotegerin and kidney disease |
| Q36319635 | Osteoprotegerin as a potential therapy for osteoporosis |
| Q82723955 | Osteoprotegerin as a potential therapy for osteoporosis |
| Q34998448 | Osteoprotegerin expression in triple-negative breast cancer cells promotes metastasis |
| Q28081803 | Osteoprotegerin in breast cancer: beyond bone remodeling |
| Q34852319 | Osteoprotegerin inhibits calcification of vascular smooth muscle cell via down regulation of the Notch1-RBP-Jκ/Msx2 signaling pathway |
| Q37011060 | Painful boney metastases |
| Q37187646 | Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments. |
| Q37682761 | Pathogenesis of osteoblastic bone metastases from prostate cancer |
| Q53625757 | Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG). |
| Q51652972 | Pharmacokinetics and disposition of recombinant human osteoprotegerin (rhOPG) after intravenous administration in female fischer rats. |
| Q33729548 | Pharmacological management of osteogenesis |
| Q89455742 | Plasma Protein Profiling Reveal Osteoprotegerin as a Marker of Prognostic Impact for Colorectal Cancer |
| Q37958733 | Potential molecular targets for inhibiting bone invasion by oral squamous cell carcinoma: a review of mechanisms. |
| Q34913054 | RANK ligand and the regulation of skeletal remodeling |
| Q36600255 | RANK ligand inhibition with denosumab for the management of osteoporosis |
| Q34209272 | RANK, RANKL and OPG Expression in Breast Cancer - Influence on Osseous Metastasis |
| Q37199218 | RANK, RANKL and osteoprotegerin in bone biology and disease. |
| Q57226639 | RANKL expression is related to treatment outcome of patients with localized, high-grade osteosarcoma |
| Q37532561 | RANKL inhibition for the management of patients with benign metabolic bone disorders. |
| Q36973041 | RANKL inhibition through osteoprotegerin blocks bone loss in experimental periodontitis. |
| Q57904702 | RANKL inhibition: Clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases |
| Q89967663 | RANKL/RANK System-Based Mechanism for Breast Cancer Bone Metastasis and Related Therapeutic Strategies |
| Q60917149 | RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives |
| Q40606140 | RNA aptamers selected against the receptor activator of NF-kappaB acquire general affinity to proteins of the tumor necrosis factor receptor family |
| Q39208355 | Rapamycin increases neuroblastoma xenograft and host stromal derived osteoprotegerin inhibiting osteolytic bone disease in a bone metastasis model |
| Q36860987 | Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. |
| Q35165886 | Role of RANKL-RANK/osteoprotegerin molecular complex in bone remodeling and its immunopathologic implications |
| Q37571986 | Role of denosumab in breast cancer |
| Q36891815 | Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system |
| Q83425416 | Significance of serum osteoprotegerin and receptor activator of nuclear factor κB ligand in Japanese prostate cancer patients with bone metastasis |
| Q38009712 | Skeletal and extraskeletal actions of denosumab. |
| Q50673485 | Sortase A-aided Escherichia coli expression system for functional osteoprotegerin cysteine-rich domain. |
| Q27665673 | Structure-based development of a receptor activator of nuclear factor- B ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis |
| Q39995055 | Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis |
| Q38081245 | Targeting RANKL in breast cancer: bone metastasis and beyond |
| Q27024561 | Targeting tumor-stromal interactions in bone metastasis |
| Q50175870 | The Biology of Bone Metastasis |
| Q33279942 | The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys |
| Q56546058 | The effect of alendronate on the expression of osteopontin and osteoprotegerin in calcified aortic tissue of the rat |
| Q53621774 | The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice. |
| Q37167038 | The effects of RANKL inhibition on fracture healing and bone strength in a mouse model of osteogenesis imperfecta |
| Q37136324 | The pathogenesis of the bone disease of multiple myeloma. |
| Q34571005 | The pharmacokinetics and pharmacodynamics of denosumab in patients with advanced solid tumours and bone metastases: a systematic review |
| Q38056541 | The role of osteoprotegerin in cardiovascular disease |
| Q36491430 | The role of the bone microenvironment in skeletal metastasis. |
| Q37368570 | Therapeutic implications of osteoprotegerin |
| Q30311918 | Transforming Growth Factor-Beta in Osteolytic Breast Cancer Bone Metastases |
| Q34441944 | Treatment and prevention of bone complications from prostate cancer |
| Q30868833 | Treatment of multiple myeloma bone disease: experimental and clinical data. |
| Q36902828 | Treatment strategies for bone disease |
| Q83202594 | Tumor bone disease |
| Q21195416 | Tumor metastasis to bone |
| Q35611366 | Variants of Osteoprotegerin Lacking TRAIL Binding for Therapeutic Bone Remodeling in Osteolytic Malignancies. |
| Q81408333 | [Clinical relevance of biomarkers in cancer related bone disease] |
| Q82908447 | [Pain and bone metastases] |
Search more.